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Abstract
Objectives: Mobile apps are useful tools in e-health and self-
management strategies in disease monitoring. We evaluated the
Harvey–Bradshaw index (HBI) mobile app self-administered by
the patient to see if its results agreed with HBI in-clinic assessed
by a physician.
Methods: Patients were enrolled in a 4-month prospective study
with clinical assessments at months 1 and 4. Patients completed
mobile app HBI and within 48h, HBI was performed by a phy-
sician (gold standard). HBI scores characterized Crohn’s disease
(CD) as remission <5 or active ‡5. We determined agreement per
item and total HBI score and intraclass correlation coefficients
(ICCs).Bland–Altmanplotwasperformed.HBI changes indisease
activity from month 1 to month 4 were determined.
Results: A total of 219 patients were enrolled. All scheduled
assessments (385 pairs of the HBI questionnaire) showed a
high percentage of agreement for remission/activity (92.4%,
j = 0.796), positive predictive value (PPV) for remission of
98.2%, and negative predictive value of 76.7%. High
agreement was also found at month 1 (93.15%, j = 0.82) and
month 4 (91.5%, j = 0.75). Bland–Altman plot was more
uniform when the HBI mean values were <5 (remission). ICC
values were 0.82, 0.897, and 0.879 in all scheduled as-
sessments, 1 and 4 months, respectively.
Conclusions: We found a high percentage of agreement
between patients’ self-administered mobile app HBI and
in-clinic physician assessment to detect CD activity with a
remarkably high PPV for remission. The mobile app HBI
might allow a strict control of inflammation by remote
monitoring and flexible follow-up of CD patients. Reduction
of sanitary costs could be possible.
Keywords: behavioral health, e-health, home health moni-
toring, telehealth, telemedicine
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Introduction
C
rohn’s disease (CD) is a chronic inflammatory dis-
order of the gastrointestinal tract of increasing in-
cidence and prevalence, which requires life-long
medical treatment to maintain remission and reduce
digestive damage.1,2
The general course of CD is extremely unpredictable, charac-
terized by periods of remission and activity. Clinical assessment
of disease activity is important for early control of inflammation,
to prevent disease progression and to improve long-term out-
comes. Exacerbation is associated with symptoms, such as diar-
rhea, abdominal pain, and/or weight loss, but flare-ups rarely
coincide with the outpatient clinic visits.1,3
The ideal approach for the control of the disease would be
real-time monitoring of patients’ symptoms. Telemedicine
systems, based on patient-reported CD activity, could improve
flare detection, help implement tight control strategies, and
avoid unnecessary clinical evaluation of patients in remission,
thus optimizing the use of the health care resources. To
achieve these goals, a patient-friendly assessment tool,
available for recording data in real-time would be required.
Mobile applications represent a promising telemedicine tool
to facilitate self-management in a new model of health care,
where patients have a closer interaction with the physician
team and are involved in their decision-making process.4,5
The importance of patient-reported measures in outcome
evaluation and symptom management is increasingly recog-
nized.6,7 Furthermore, the use of patient-reported outcome
measures (PROMs) for evaluating effectiveness of inflamma-
tory bowel disease (IBD) interventions is progressively sup-
ported by the U.S. Food and Drug Administration.8,9
The use of PROMs is promising in m-health apps, which are
becoming the dominant method of e-health. Many studies
have been undertaken to assess the use of the web and mobile
applications for chronic disease management, such as hy-
pertension, diabetes, chronic heart failure, and asthma.10–13
However, accurate e-monitoring tools for disease activity in
IBD are scarcely developed.
Recently, the diagnostic performance of the Walmsley in-
dex self-administered by the patient has been evaluated
through a Web-based platform to detect activity/remission in
patients with ulcerative colitis (UC). A good diagnostic
agreement has been obtained when compared with the in-
clinic index utilization by the physician (CRONICA study).14,15
The advantage of the use of a standardized index in the
monitoring of a disease is its established relationship with
activity/remission. In CD, the most used indexes for in-clinic
evaluation are the Crohn’s disease activity index (CDAI)16 and
the Harvey–Bradshaw index (HBI).17 Although CDAI is con-
sidered the gold standard index, it is not practical and is es-
sentially limited to clinical trials. The HBI has a very good
correlation with the CDAI with the advantage of being easy to
use in clinical practice.17–19
Reports of diagnostic indexes to evaluate activity by the
patients in CD using m-health apps are scarce, and, to the best
of our knowledge, there are no studies comparing the diag-
nostic performance of a self-administration mobile app and
an in-clinic standardized index such as the HBI.20
In the MediCrohn study, we aimed to evaluate if the HBI
adapted to a mobile app, used as self-control questionnaire, is
as useful as the original HBI questionnaire assessed by the
physician to discriminate between activity and remission of
CD. The HBI mobile app (HBImApp) could be used as part of




Patients with established CD attending IBD outpatient clinics
from April 2016 to June 2017 at 14 hospitals in Spain were
invited to participate in a prospective, non-interventional, 4-
month follow-up study, to assess the diagnostic performance
(remission/activity of CD) of the self-administered HBImApp
compared with the same index evaluated in-clinic by the gas-
troenterologist. The study was approved by the corresponding
Clinical Research Ethics Committees.
The inclusion criteria were: (1) 18 years of age or older, (2)
diagnosis of CD for >6 months confirmed by Lennard-Jones
criteria, (3) familiarity with mobile apps or internet use, (4) a
mobile phone with internet connection, and (5) signed in-
formed consent for the study. Exclusion criteria were: (1) se-
vere CD flares, (2) mental disorder or limitations that prevent
accurate interpretation of the questionnaires, and (3) other
relevant concomitant clinical conditions.
After inclusion in the study, patients and physicians re-
ceived an explanation of the procedures and were trained by
using a demonstration of the mobile application. To ensure
privacy and security, patients had access to a personalized and
private password-protected website (IBD training platform:
www.educainflamatoria.com/entrenaeii), where the HBImApp
version was available for completion. This platform was de-
veloped by IBD Unit of the Hospital-University Complex of
Ferrol and CATCRONIC HEALTH Company.
Sample size calculation was based on a desired precision of
–4%, with a confidence level of 95%, for the global agreement
between both measurements (patient and physician) of at least
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80%. If each subject was evaluated at 1 and 4 months, 384
pairs of patient–physician questionnaires were needed and
192 patients must be enrolled. Assuming an expected 20%
drop out rate, the number of subjects to be recruited was
230.
DEMOGRAPHIC DATA AND CD CHARACTERISTICS
Baseline demographic data, the CD characteristics (disease
location and behavior) and surgical history related to CD were
recorded.
HBI MOBILE APP
The HBImApp is composed of 12 items in 5
domains: (1) general well-being, (2) abdomi-
nal pain, (3) number of liquid stools per day,
(4) abdominal mass, and (5) extra intestinal
manifestations of CD (arthralgia, uveitis, ery-
thema nodosum, aphthous ulcer, pyoderma
gangrenosum, anal fissure, new fistula, and
abscess). Score ranges from 0 to 16 or more
and the highest score depends on the number
of liquid stools per day. To help the patients to
identify the presence of extraintestinal mani-
festations, pictures were provided in the ap-
plication, with a clear description of each of
the hallmark symptoms (Fig. 1). Evaluation of
comprehensiveness, clarity, and readability
of app questionnaire was assessed in a group of
12 volunteers through cognitive interviews
analysis. Patients found the test easy to under-
stand, answered without supervision, and ap-
peared to be comfortable with the images and
questions. Aspects of translation equivalence
were proved.
ASSESSMENT OF PATIENT-REPORTED HBI
AND IN-CLINIC HBI
The clinical assessment of the patients, in-
cluding both mobile app self-evaluation and in-
clinic evaluation by physicians, was performed
at months 1 and 4. Short message service alerts
were programmed as reminders to complete the
HBI questionnaire through the app. Within 48 h,
the patients attended an onsite hospital ap-
pointment where the HBI was performed by the
gastroenterologist.
STATISTICAL ANALYSIS
To evaluate the self-administered HBImApp,
the HBI assessments by the physician at the
outpatient clinic was considered the gold standard.
As primary objective of the study, we determined the
percentage of total agreement between both tests to detect
activity or remission of CD. HBI scores were treated as a
dichotomous variable, scores <5 = remission and ‡5 = active
disease.18,19 Cohen’s j coefficients were calculated to correct
for the agreement expected by chance, with the following
interpretation: poor (<0), slight (0–0.20), fair (0.21–0.40),
moderate (0.41–0.60), substantial (0.61–0.80), and almost
perfect (0.81–0.99).21 Negative predictive value (NPV),
Fig. 1. Screenshots of the HBI mobile app self-administered by the patients. Pictures
of extraintestinal manifestations with a clear description of each of the hallmark
symptoms are shown. Color images are available online.
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positive predictive value (PPV), and sensitivity and speci-
ficity to detect activity with 95% confidence intervals (CIs)
were also calculated. Additionally, we examined agreement
between scores of the HBI patient/physician on the total sum
score and per item, percentages, and Cohen’s j were pro-
vided.
The level of agreement between the HBImApp assessed by
the patient and the HBI assessed by the gastroenterologist was
evaluated by intraclass correlation coefficients (ICCs), ranging
from 0 to 1. An ICC of 0.75 and above is considered ‘‘excellent.’’
The difference between each pair of measurement was analyzed
graphically as opposed to its mean by Bland–Altman plot
methodology.
As a secondary objective, we evaluated the correlation
between the changes in HBImApp from month 1 to month 4
assessed by the patient with the changes in the in-clinic HBI
assessed by the physician. Changes in HBI questionnaire
scores were categorized as follows: worsening (increase ‡3
points), stable (variations not exceeding 2 points), and im-
proving (decrease ‡3 points), and the percentage of agreement
and the Cohen’s j were calculated.18,19
Results
Between April 2016 and June 2017, a total of 219 patients
(116 females and 103 males), with mean age 36 – 8 years
were enrolled. Baseline characteristics are summarized in
Table 1.
A total of 385 pairs of questionnaires were valid to esti-
mate the percentage of total agreement between the self-
administered HBImApp and in-clinic gastroenterologist
evaluation to detect activity or remission of CD. A total of
219 pairs of questionnaires from month 1 and 166 from
month 4 were analyzed. Most of the patients filled out both
mobile app HBI questionnaires, but 53 patients did not at-
tend their medical check-up on the scheduled date at month
4 and were excluded from the second analysis. Results for
the patients’ and physicians’ assessment of CD activity or
remission in overall scheduled evaluations (A) and at 1- and
4-month evaluations (B and C, respectively) are shown in
Table 2.
Percentage of agreement and predictive values between the
self-administered HBImApp and in-clinic gastroenterologist
evaluation with regard to the status of CD is shown in Table 3.
The overall schedule evaluation percentage of agreement was
92.46% (95% CI 88.4–94.8) with a Cohen’s j coefficient of
0.796 (substantial agreement). Sensibility, specificity, PPV
predicting clinical remission, and NPV are shown in Table 3.
The overall agreement from month 1 assessment was
93.15% (95% CI 91.2–94.3) with almost perfect agreement
of Cohen’s j coefficient of 0.82. The study showed strong
test–retest reliability with 91.5% (95% CI 87.8–93.1) of
agreement at the 4-month assessment, Cohen’s j = 0.75
(substantial agreement) (Tables 2 and 3). There was good
agreement for active versus inactive categorization at the
two measurement time points. No differences by gender,
age, internet use, educational level, or marital status were
observed.
Table 1. Characteristics of the 219 Patients Included
in the MediCrohn Study
Median age, years (IQR 25–75) 36 (32–41)
Male, n (%) 103 (47.03)
Smoking, n (%) 47 (21.66)
Educational level, n (%)
Primary or secondary school 47 (21.46)
Professional studies 58 (26.48)
University degree 90 (41.10)
Internet use, n (%)
Three times per week 209 (95.43)
Occasionally 10 (4.57)
Clinical characteristics
Median age at diagnosis in years (IQR 25–75) 25 (22–28)








Perianal CD present 38 (17.36)
Surgical history, n (%) 64 (29.22)
EIM, n (%) 60 (27.4)
Active disease (HBI ‡5) (%) 28.8
Medications at baseline, n (%)
Biological treatment 72 (35.31)
Thiopurines 94 (46.09)
Steroids 12 (5.88)
CD, Crohn’s disease; EIM, extraintestinal manifestation; HBI, Harvey–Bradshaw
index; IQR, interquartile range.
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The mean of total HBI score of the 385 self-administered
questionnaires was 3.3 (95% CI 2.9–3.8), and the mean value of
those administered by the physician was 2.7 (95% CI 2.4–3.0)
( p < 0.001). A large patient/physician agreement was observed,
agreeing exactly on the questionnaire score in 56.4% of the
cases. Differences of only 1 or 2 points were observed in 22.3%
and 11.9% of cases, respectively. A difference of >2 points
between the patient and the gastroenterologist HBI scores was
observed in 9.4%.
Figure 2 shows the Bland–Altman plot of the difference
between the assessment HBI (patient–physician) and the av-
erage of each pair of observations. The median of the differ-
ence between the score shows high dispersion in all scheduled,
1- and 4-month evaluations. The dots distribution is more
uniform when the mean values are <5, which corresponds
with the score for remission of the HBI.
Lastly, there is a high ICC globally, ICC (95% CI) = 0.82
(0.860–0.904), and both at month 1 = 0.879 (0.849–0.909) and
at month 4 = 0.885 (0.853–0.918).
Table 4 shows the percentage of agreement between patient/
physician score in the different HBI domains. The lowest agree-
ment was seen for number of liquid or soft stools per day domain
(64.9% and moderate Cohen’s j value). Number of depositions
per day was higher in patient score than in the physician 1.
Extraintestinal manifestations were observed in 27.4% of
the cases with a high percentage of agreement, all of them
over 90%.
The ability to detect changes in disease activity (respon-
siveness) of app-administered HBI at 1 and 4 months was
tested in a subset of 166 patients (Table 5). The percentage of
agreement was 80.1% with a moderate correlation between
the two questionnaires (Cohen’s j coefficient: 0.506).
Discussion
e-Health technologies such as web-based interventions, virtual
clinics, smartphone applications, and telemedicine are increas-
ingly used for IBD patients’ follow-up and continue to impact on
health care. The link between e-health technologies with con-
ventional clinical indexes and patient-reported outcomes could
be cost effective and could facilitate the self-management of
patients with IBD in a new model of patient-centered care.20,22
Table 3. Percentage of Agreement and Predictive Values of Self-Administered Patient Mobile App HBI With Regard
to the Gastroenterologist In-Clinic HBI Assessment
ALL SCHEDULED
EVALUATION (N = 385)
MONTH 1
EVALUATION (N = 219)
MONTH 4
EVALUATION (N = 166)
Overall percentage of agreement 92.46 (88.4–94.8) 93.15 (91.2–94.3) 91.5 (87.8–93.1)
Cohen’s j coefficient 0.796 0.824 0.753
Negative predictive value 76.7 (67.3–84.5) 79.4 (67.3–88.5) 72.5 (56.1–85.4)
Positive predictive value 98.2 (95.9–99.4) 98.7 (95.4–99.8) 97.6 (93.2–99.5)
Specificity 94 (86.7–98) 96.2 (86.8–99.5) 90.6 (75–98)
Sensibility 92 (88.4–94.8) 92.2 (87.1–95.8) 91.8 (85.8–95.8)
With the exceptions of Cohen’s j coefficient all values are presented as percentage (95% confidence interval).
Table 2. Results of Patient’s Self-Assessment Through











Remission (HBI <5) 277 5 282
Activity (HBI ‡5) 24 79 103
Total 301 84 385
B
Remission (HBI <5) 154 2 156
Activity (HBI ‡5) 13 50 63
Total 167 52 219
C
Remission (HBI <5) 123 3 126
Activity (HBI ‡5) 11 29 40
Total 134 32 166
A. All pairs of questionnaires (n = 385, j = 0.796).
B. Pairs of questionnaires from month 3 (n = 219, j = 0.824).
C. Pairs of questionnaires from month 6 (n = 166, j = 0.753).
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The use of PROMs to support routine
IBD care is not widespread and suggests
that existing questionnaires lack rele-
vance to day-to-day decisions or are too
cumbersome to administer.23 Recently,
de Jong et al.20 performed a systematic
review to identify available PROMs on
IDB activity and whether they can be
used effectively in routine practice,
clinical trials, telemedicine systems, or
value-based health care programs.
Development and validation of a new
PROM may take several years; hence to
adapt PROMs from existing indexes to
e-health instruments, could be useful
until more reliable instruments are
available.24
We adapted the HBI to a mobile
app because the data collection and
calculation of HBI is simple, easily
translatable into a patient-based ques-
tionnaire,17,19,25 and offers the possi-
bility of capturing PROMs with minimal
user burden.
In this study, we found that the
patient-self-administered HBImApp
questionnaire had a high agreement rate
compared with the in-clinic physician-
administered original HBI questionnaire
to assess CD activity with a high accu-
racy (sensibility 92%; specificity 94%)
and a noteworthy PPV for remission,
suggesting that patients whose score
with the HBImApp indicated remission
will be very unlikely to have active dis-
ease. The reliability of the mobile app
patient’s-self-administered HBI was
confirmed by the findings at the 3-
month follow-up. The remarkably high
PPV suggests that stable patients or
those in remission might benefit from
more flexible monitoring, including
remote self-evaluations. Tools like
HBImApp could allow better patient/
hospital or patient/physician commu-
nication, potentially generating cost
savings in the management of CD pa-
tients, and would be useful in routine
medical care.26
Fig. 2. Bland–Altman plot for all schedule evaluation (a), 1 month (b) and 4 month (c) of the
agreement between the patient self-assessment HBI (app mobile) and in-clinic physician
assessment. HBI, Harvey–Bradshaw index.
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While the evidence supporting the utility of telemedicine
and internet-based interventions in IBD is emerging, the ev-
idence supporting the efficacy of mobile phone apps in the
CD setting is scarce.20,22 Although it was not a mobile app,
Kim et al.,27 found that web-based diaries using the HBI can
be useful in the monitoring of clinical disease activity in
patients with CD, with good correlation between HBI com-
pleted through the web by the patient and the CDAI calcu-
lated by the medical staff. Recently, Van Deen et al.9
developed and validated a scoring system to monitor disease
activity in patients with CD and UC that can be used with
mobile technologies. Bennebroek et al.25 assessed the per-
formance of the HBI filled out by the patient on paper
compared with that of the treating physician, but to the best
of our knowledge, this is the first time that diagnostic per-
formance of HBImApp has been evaluated and reliability and
responsiveness of the app was tested. Our results show higher
percentage of agreement and Cohen’s j score regarding ac-
tive disease versus remission with HBImApp than reported
previously with paper questionnaires. Similar findings are
reported by Larsen et al.28 using HBI touch screen, maybe
related to a lower probability of unanswered questions on
digital versions.
The ICC in all scheduled, 1- and 4-month pairs of ques-
tionnaires showed almost perfect correlations. Bland–Altman
plot showed more concordance between the observers in the
low score of the scale suggesting better agreement when the
patient is in remission.
The high percentage of patient/physician agreement on
item-level HBI scores was found. The domains well-being and
abdominal pain showed the highest percentage of agreement
and the least agreement is shown in the number of stools per
day. Number of depositions per day is higher in patient score
than in that of the physician. Many patients referred to total
depositions (not only liquid or loose stools), but probably this
item will improve with the use of the mobile app HBI by the
patient. High agreement was observed in the domain ab-
dominal mass, in spite of the fact that it was evaluated by the
patient without physician intervention. Bennebroek et al.25
developed a modified patient HBI, omitting the physical ex-
amination of abdominal mass, assuming that patients cannot
adequately examine themselves. They found high agreement
to characterize CD activity between the modified HBI and the
original HBI in-clinic assessed by the physician, suggesting





1. General well being 89.6 (85.8–92.6) 0.742
2. Abdominal pain 87.7 (85.4–90.3) 0.706
3. Number of liquid or soft stools per day 69.3 (64.7–73.4) 0.567
4. Abdominal mass 91.6 (89.2–93.5) 0.491
5. Extraintestinal complications
Arthralgia 90.1 (86.3–93.1) 0.782
Uveitis 95.3 (92.1–97.7) 0.529
Erythema nodosum 97.7 (94.5–98.2) 0.391
Aphthous ulcer 95.8 (92.8–97.6) 0.639
Pyoderma gangrenosum 100 1
Anal fissure 92.5 (89.1,94.7) 0.592
New fistula 96.9 (91.2–98.6) 0.318
Abscess 97.7 (94.5–99.1) 0.598
Data of agreement are presented as a percentage (95% confidence interval)
and Cohen’s j values.
Table 5. Agreement in the Change in Disease Activity from Month 1 to Month 4 Between the Patient Self-Assessed
Harvey–Bradshaw Index Mobile App and the Gastroenterologist In-Clinic Assessment
CHANGE IN THE PHYSICIAN HBI
CHANGE IN THE PATIENT HBI
WORSENING STABILITY IMPROVING TOTAL
Worsening, n (%) 7 (4.2) 7 (4.2) 1 (0.6) 15 (9)
Stability, n (%) 7 (4.2) 109 (65.7) 15 (9.0) 131 (78.9)
Improving, n (%) 0 (0.0) 3 (1.8) 17 (10.2) 20 (12)
Total, n (%) 14 (8.4) 119 (71.7) 33 (19.9) 166 (100)
Worsening: increased in HBI ‡3 points, Stability: HBI score variation not exceeding 2 points, Improving: decreased in HBI score ‡3 points (Vermeire Clinical
Gastroenterology 2010).
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that this item could be omitted if the HBI will be used as a
PROM instrument.
To achieve our secondary objective, we scheduled a pro-
spective follow-up,with 2 evaluations of theHBI3 months apart.
We found a high patient/physician agreement in the changes in
disease activity from month 1 to month 4. These findings con-
firmed the usefulness of the HBImApp as a user-friendly tool of
e-health that allows the remote self-monitoring of disease ac-
tivity. Self-management strategies through e-health tools pro-
vide the patient with opportunities for easy access to medical
care and individualized treatment in a medical system with in-
creasing patient-centered care focus. An e-Health-Enhanced
Chronic Care Model is being proposed to improve health care
quality. e-Health tools can be used to increase efficiency when
patients manage their own chronic illnesses.29
One of the strengths of this study is that the patients were
familiar with HBI questions, therefore, differences in answers
between paper questionnaires and mobile app were not con-
founded by difficulties in understanding the questions. With the
HBImApp it is not possible to proceed without answering, which
probably decreased the number of missing data in the ques-
tionnaire. The mobile app was completed within the 48h before
physician evaluation, thereby minimizing memory biases.
The current study has several limitations. First, a possible
selection bias because the patients enrolled must be familiar
with mobile apps or internet use and have a mobile phone with
internet connection. Second, we failed to collect 53 pairs of
HBI questionnaire in the second assessment because patients
did not attend their medical check-up on the scheduled date.
Third, the study may not be representative for elderly patients,
because we did not include enough patients above 65 years to
investigate app use in this group of age. Finally, the mobile
app was validated against the original HBI instead of endos-
copy, gold standard to validate PROM measuring disease ac-
tivity, because HBI do not accurately reflect endoscopic
disease activity in patients with CD.
Conclusions
Our results showed a high percentage of agreement between
self-administered HBImApp and in-clinic physician assess-
ment to categorize activity/remission in CD with a remarkably
high accuracy and high PPV for remission. Moreover, the
HBImApp showed good reliability and responsiveness to
changes in disease activity. In this regard, it could be con-
sidered as an adequate m-Health PROM instrument for CD
activity monitoring for use in clinical practice. Possible ben-
eficial effects in patient disease control, less frequent outpa-
tient’s visits of patients in remission, and reduction of sanitary
costs must be considered.
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